Lee Soo Yeon, Rim Yonghoon, McPherson David D, Huang Shao-Ling, Kim Hyunggun
Division of Cardiovascular Medicine, Department of Internal Medicine, The University of Texas, Health Science Center at Houston, 6431 Fannin St. MSB 1.246, Houston, TX, USA.
Biomed Mater Eng. 2014;24(1):61-7. doi: 10.3233/BME-130784.
Breast cancer is the most common type of cancer occurring among women in the United States. Nitric oxide (NO) is endogenous signaling molecules that regulate biological processes. NO has the potential to induce either cancer progression or cancer cell apoptosis depending on intra-tumoral NO concentration. High levels of NO have a cytotoxic effect on cancer cells. A novel cytotoxic gas delivery system has been developed using NO-loaded echogenic liposomes (ELIP) for breast cancer treatment. Empty ELIP and NO-ELIP were prepared using the previously developed freezing-under-pressure method with modified lipid composition. Echogenicity of NO-ELIP was measured to determine the stability of NO-ELIP. Two types of breast cancer cell (BCC) lines, MDA-MB-231 and MDA-MB-468, were utilized. MTT assay was performed after NO-ELIP treatment to determine BCC viability. Echogenicity data demonstrated improved stability of NO-ELIP with the use of BSA for resuspension of NO-ELIP. Cell death induced by NO-ELIP was not from lipid cytotoxicity but from NO. The cytotoxic effect of NO-ELIP on BCC was highly dependent on NO-ELIP concentration. NO-ELIP in concentration of 1.0-2.0 mg/ml induced dramatically decreased BCC viability. This novel cytotoxic gas delivery nanomedicine using liposomal carriers, NO-ELIP, has the potential to provide improved therapeutic effect for breast cancer treatment.
乳腺癌是美国女性中最常见的癌症类型。一氧化氮（NO）是调节生物过程的内源性信号分子。根据肿瘤内NO浓度，NO有可能诱导癌症进展或癌细胞凋亡。高水平的NO对癌细胞具有细胞毒性作用。一种新型的细胞毒性气体递送系统已被开发出来，使用负载NO的超声造影脂质体（ELIP）用于乳腺癌治疗。使用先前开发的压力下冷冻方法和改良的脂质成分制备了空白ELIP和NO-ELIP。测量NO-ELIP的回声性以确定其稳定性。使用了两种乳腺癌细胞（BCC）系，MDA-MB-231和MDA-MB-468。在NO-ELIP处理后进行MTT试验以确定BCC的活力。回声性数据表明，使用牛血清白蛋白（BSA）重悬NO-ELIP可提高其稳定性。NO-ELIP诱导的细胞死亡不是来自脂质细胞毒性，而是来自NO。NO-ELIP对BCC的细胞毒性作用高度依赖于NO-ELIP的浓度。浓度为1.0-2.0mg/ml的NO-ELIP可显著降低BCC的活力。这种使用脂质体载体的新型细胞毒性气体递送纳米药物NO-ELIP有可能为乳腺癌治疗提供更好的治疗效果。
